Unicycive reports FY2023 net loss of $31.4M; OLC topline data expected Q2 2024

Unicycive Therapeutics, Inc.

FY2023 net loss $31.4M ($1.28/share) vs $18.1M ($1.20/share) in FY2022.
Cash $9.7M at Dec 31, 2023; subsequent $50M private placement extends runway into 2026.
Pivotal OLC trial enrollment completed; topline data expected in Q2 2024.
UNI-494 granted FDA Orphan Drug Designation for delayed graft function; Phase 1 SAD complete, MAD ongoing.
R&D expenses $12.9M, G&A $8.5M; licensing revenue $0.7M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Unicycive Therapeutics, Inc. reported the year ended December 31, 2023 results: net income Net loss attributable to common stockholders for the year ended December 31, 2023 was $31.4 million, or $1.28 per share.

Period: the year ended December 31, 2023
Net income: Net loss attributable to common stockholders for the year ended December 31, 2023 was $31.4 million, or $1.28 per share
Result: reported results

Exact text from the filing

Net loss attributable to common stockholders for the year ended December 31, 2023 was $31.4 million, or $1.28 per share of common stock, compared to a net loss of $18.1 million, or $1.20 per share of common stock, for the same period in 2022.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Unicycive Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-027373

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.